SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Technical Considerations for Left Main PCI1

Patients undergoing PCI are becoming more complex and that includes treating left main vessels which can be technically challenging. There are important considerations when treating these types of vessels including: overexpansion and radial strength capabilities as well as the stent's ability to help the vessel heal. The Synergy stent meets those types of requirements.

Left main vessels are large (>5.5mm on average2) making stent overexpansion capabilities critical.1

The SYNERGY Stent is indicated for treatment of patients presenting unprotected left main coronary artery lesions and has a labeled overexpansion indication of up to 5.75mm allowing the physician to customize the stent to the appropriate vessel size.
SYNERGY Stent Overexpansion Capabilities

SYNERGY Stent System DFU
 

Left Main Vessels require stents with significant radial strength.1

The SYNERGY 4.00mm diameter stent utilizes a customized architecture for strength and a 9% thicker PtCr strut design3 which offers excellent radial strength. In addition, radial strength increases as diameter increases based on bench test measurements.

SYNERGY 4.0mm Diameter Stent's Radial Strength Increases as the Diameter
is Overexpanded

Radial Strength Bench Test

Adapted from a presentation by Jiang Ming Fam, MD at AsiaPCR 2015. 4.0mm diameter x 16mm length stent shown; n=10. Data pending publication. Bench test results not necessarily indicative of clinical performance.

 

SYNERGY Stent's PtCr Stent Design Combine for Greater Radial Strength

Radial Strength Bench Test

Stent Radial Strength

Bench testing performed by Boston Scientific Corporation. Data on file at Boston Scientific. All stents 2.5mm. SYNERGY Stent n=5, all other stents are n=3. Bench test results not necessarily indicative of clinicial performance.

 


Left Main PCI and Vessel Healing1

The SYNERGY Stent’s bioabsorbable polymer and abluminal coating are designed for early healing as the polymer is gone when no longer needed, shortly after completion of drug elution at 3 months.
 

IDEAL Left Main – An Investigator Sponsored Clinical Study4 Evaluating Stenting in this Complex Vessel Type

Boston Scientific is committed to supporting studies evaluating the SYNERGY Stent in patient populations that interventional cardiologists see in their everyday practice; including left main stenting.
 
IDEAL Left Main Clinical Study

For more information on the SYNERGY Investigator Sponsored Research
Top